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Transgenic mouse models to study human mineralocorticoid the regulation of hydroelectrolytic homeostasis in sodium-
receptor function in vivo. The mineralocorticoid receptor (MR) transporting tight epithelia such as distal nephron [2, 3],
is a transcription factor that mediates aldosterone action. MR colon [4, 5], lung [6], and salivary and sweat glands [2, 7].is expressed in a wide variety of tissues, most notably in sodium-
In such epithelial target cells, the mineralocorticoid spec-transporting epithelia, but also in nonepithelial cells of the
ificity of aldosterone action is given by the enzyme 11b-cardiovascular and central nervous systems. However, molecu-
lar mechanisms underlying mineralocorticoid signaling and the hydroxysteroid dehydrogenase 2 (11HSD2) [8], which
primary mineralocorticoid-regulated genes are not fully identi- converts active glucocorticoids into inactive metabolites
fied. We recently showed that the human MR (hMR) gene [9–11]. However, other mineralocorticoid selectivity-possesses two first 59-untranslated exons 1a and 1b, and demon-
conferring mechanisms are necessary to fully accountstrated that the 59-flanking regions of these exons, named P1
for receptor specificity [12]. For instance, at the receptorand P2, respectively, are functional promoters that differ by
their basal and corticosteroid-regulated transcriptional activi- level, MR is able to discriminate between aldosterone
ties. To gain insight into the tissue-specific expression and func- and glucocorticoids in ligand-dependent conformational
tion of MR, we have established transgenic mouse models
changes and stabilization of the ligand-binding domainusing both targeted oncogenesis and receptor overexpression
[13, 14], as well as in transcriptional activation [15, 16].strategies. P1 and P2 promoters were used to direct expression
of the large T antigen (TAg) of SV40 in constitutively MR- MR is also expressed in nonepithelial tissues such as the
expressing cells. P1.TAg mice developed lethal hibernomas, heart [17, 18], some areas of the brain [19–21], large
while P2.TAg animals died from cerebral neuroectodermal blood vessels [22, 23], and mononuclear leukocytes [24],
tumors and leiomyosarcomas. Quantification of TAg messen-
in which specific aldosterone actions have been de-ger RNA levels revealed that P1 and P2 were differentially
scribed, but their mineralocorticoid specificity is not fullyutilized. P1 promoter was transcriptionally active in all MR-
expressing tissues and importantly directed an appropriate understood.
transgene expression in the distal nephron. Conversely, P2 The ligand-activated MR is translocated in the nucleus
activity was weak and spatially restricted. Several immortalized and acts as a transcription factor after its interaction with
cell lines were established, thus constituting valuable models
the consensus glucocorticoid response element (GRE)to investigate on aldosterone-regulated proteins. We also used
sequences [25]. It is assumed that MR can directly inter-P1 and P2 to target overexpression of hMR cDNA in mice.
Phenotypic characterization of these mice is currently under act with coactivators or corepressors, which will modu-
investigation. Some transgenic lines should represent useful late the activity of the general transcription machinery
systems to further explore multiple functions of MR in vivo. [26]. Thus, MR could activate or inhibit transcription of
target genes whose identification is under intense investi-
gation.
Aldosterone is a major regulator of salt balance and The genomic structure of the human MR (hMR) gene
blood pressure, exerting its effects via the mineralocorti- has recently been elucidated. This gene contains 10 ex-
coid receptor (MR), a transcription factor belonging to ons, two different 59 untranslated exons, namely exon
the steroid receptor superfamily [1]. MR is closely re- 1a and 1b, spliced alternatively onto the exon 2, which
lated to the glucocorticoid receptor (GR), and it can contains the MR translation start site, giving rise to two
indifferently bind mineralocorticoid and glucocorticoid distinct mRNA isoforms: hMRa and hMRb [27]. In situ
hormones. MR is widely expressed, but at a relatively hybridization studies indicated that these two transcripts
low level, in a large variety of tissues. MR participates in were coexpressed in human tissues at approximately the
same level in aldosterone target tissues examined [28].
Furthermore, a third 59 untranslated exon (exon 1g) hasKey words: aldosterone, oncogenesis, gene promotion, transcription
factor, epithelia. been identified in the rat [29], sharing 75% homology
with a human sequence located upstream of exon 1b;Ó 2000 by the International Society of Nephrology
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however, we failed to detect such a splice variant in approximately one tenth that of P1. No difference in
normalized luciferase activities was observed between thehuman kidney [30]. Collectively, this raises the question
of how receptor isoforms are generated and whether longest SspI-SspI fragment of P2 and the shorter 431 bp
length SacII-SspI construct. Interestingly, both P1 andregulation of hMR expression might result from differen-
tial utilization of alternative promoters. As a result, we P2 promoter activities were up-regulated by glucocorti-
coids, but only the distal P2 promoter was stimulated byhave analyzed the 59-flanking regions of exons 1a and
1b, named P1 and P2, respectively. Their sequences are aldosterone treatment. We also demonstrated that MR
and GR were able to synergistically activate the distalGC rich and possess numerous Sp1 sites, but they lack
a TATA box. Transient transfection assays in different promoter, suggesting MR/GR heterodimerization as
previously described [31]. Even though two GRE-likecell types demonstrated that P1 and P2 are functional
promoters [28]. sequences have been identified in P1 and P2 regions, no
binding of hGR, hMR, or both was detected by gel shiftStudy of hMR promoters in an in vivo context is an
essential step in understanding the regulation of hMR or DNAse protection assays, suggesting an indirect effect
of corticosteroid receptors in these promoters.expression fully. The generation of transgenic mouse
models using P1 or P2 fragments to direct expression of The influence of corticosteroid hormone status on MR
mRNA or proteins expression is still a matter of contro-a reporter gene constitutes an appropriate experimental
approach. Our strategy is illustrated in Figure 1. On versy. Indeed, several animal studies had reported oppo-
site results on the effect of adrenalectomy on MR levelsone hand, targeted oncogenesis, which consists in driving
expression of the oncogene large T antigen (TAg) of the in rat kidney and hippocampus [29, 32–34], whereas no
variation was observed in rat colon [35, 36]. These differ-SV40 virus by either P1 or P2 promoter, was initially
used. This allows us at the same time to analyze the tissue- ent results could be attributed to the experimental condi-
tions used and tissues and/or species analyzed. Morespecific utilization of alternative promoters and to estab-
lish novel cell lines given the high transforming proper- importantly, the results might also largely depend on the
MR level examined either at the mRNA or protein level.ties of TAg. On the other hand, in order to better eluci-
date MR function in different types of tissues, a targeted Transcriptional or post-transcriptional events are proba-
bly involved in the modulation of synthesis rate, stabilityoverexpression of recombinant hMR driven by P1 or
P2 was initiated in transgenic mice to create potential of transcripts, or the receptor protein. Thus, regulatory
mechanisms controlling intracellular MR levels are ex-physiopathologic models. This review briefly describes
some of our recent data and views on the role played by tremely complex and may involve differential utilization of
alternative promoters with variable basal transcriptionalMR in physiological and pathophysiological processes.
strength and sensitivity to hormonal modulation [28].
CHARACTERIZATION OF HUMAN
MINERALOCORTICOID RECEPTOR TISSUE-SPECIFIC EXPRESSION OF HUMAN
MINERALOCORTICOID RECEPTOR IN VIVOPROMOTERS IN VITRO
To identify the regulatory elements of the hMR gene, Different isoforms of the glucocorticoid and MRs gen-
erated by alternative utilization of 59-untranslated exonsa phage library had been constructed from a YAC DNA
containing the entire hMR gene. One phage clone was have been previously identified [27, 29, 37]. This type of
genomic organization allows differential control of geneisolated and mapped by restriction enzyme digestion and
Southern blot analysis. It contained approximately 15 expression by alternative promoters in a tissue-specific
and/or developmental manner. Analysis of the relativekb of hMR 59-flanking region. A 1.2-kb HindIII-AvaII
fragment containing 216 bp of exon 1a and 965 bp of its amount of hMRa and hMRb messenger isoforms, which
only differ by their first exon, 1a or 1b, could facilitate59-flanking region (P1) was subcloned, as well as a 1.8 kb
SspI-SspI fragment containing 1673 bp upstream se- our understanding of hMR tissue-specific expression. Be-
cause of the ethical problem of obtaining access to aldo-quences (P2) and 123 bp of exon 1b. Both CG-rich se-
quences present numerous Sp1-binding sites characteris- sterone target tissues in human, such a study was a diffi-
cult task. We investigated the expression of hMRtic of TATA-less promoters. A series of deletion mutants
of these regions was inserted into a luciferase reporter transcripts in the human renal, cardiac, skin, and colonic
tissue samples by in situ hybridization [38]. Discrimina-plasmid and used in transient transfection assays to de-
termine functional activities of the proximal P1 or distal tion between the two messenger isoforms was performed
using exon 1a- and 1b-specific riboprobes. The totalP2 fragments [28]. We showed that the BH construct
(2341, 1128) containing 535 bp of P1 exhibited the amount of hMR mRNA was measured with a common
exon 2 riboprobe. Specific signals were quantitated byhighest basal activity, suggesting the existence of silencer
regulatory elements upstream 2341 in the HA fragment. computer-assisted densitometry. The relative level of
hMR transcripts detected with the exon 2 probe wasThe P2 sequences possessed weak promoter activities,
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Fig. 1. Strategies used to study human mineralocorticoid receptor expression and function.
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as follows: distal nephron 5 sweat glands 5 colon . mice carrying large TAg cDNA under the control of P1
or P2 sequences. The phenotypic features of P1 andepidermis . heart. More importantly, the two hMR
mRNA isoforms were present in all typical aldosterone P2.TAg mice were somehow unexpected. Whereas no
tumor was apparent in classic aldosterone target tissues,cells such as in cortical collecting ducts, colonic entero-
cytes, sweat gland ducts, cardiomyocytes, and keratino- all of the 10 P1.TAg founder animals developed lethal
dorsal liposarcomas from brown fat origin, so-called hib-cytes, and were coexpressed at approximately the same
level. This hMR expression pattern is at variance with ernomas [43]. Death occurred within the first weeks of
life (2 to 17 weeks), preventing the generation of anythat reported in the rat by RNAse protection assay in
which MRa was prevailing over MRb isoform in kidney transgenic line. Three P2.TAg transgenic lines have been
obtained. The founder 55 and the eight F1 animals line[29], but was equally expressed in hippocampus. How-
ever, a relative abundance of hMRa and b transcripts 45 died before breeding. All founders and F1 P2.TAg
animals developed cerebral primitive neuroectodermalcompared with that of exon 2 containing mRNA strik-
ingly differs among tissues. In kidney, the signals corre- tumors (PNETs). Some of them also presented thymus
hyperplasia and died between six months and one yearsponding to 1a and 1b mRNAs were clearly lower than
that given by the exon 2-specific probe and, therefore, of age. The formation of PNET did not systematically
occur in F2 generation animals of line 54, however, facialfully accounted for the expression of the common exon
2 containing mRNA. In contrast, in the heart, 1a- and leiomyosarcomas generally arose from the lips or eyelids.
The distinct phenotype among P1 and P2.TAg animals1b-containing transcripts are expressed in the cardiomy-
ocytes at approximately fourfold higher levels than exon already demonstrated differences in hMR promoter utili-
zation in vivo [Le Menuet et al, J Biol Chem 2000 (in2-containing messengers, strongly suggesting the exis-
tence of other hMR mRNA variants that could arise press)].
The mouse MR expression pattern was initially exam-from tissue-specific alternative mRNA splicing.
In an attempt to study hormonal regulation of hMR ined in wild-type animals by ribonuclease protection
assays (RPA), and quantitative analysis of specific signalsisoforms expression, quantitative analysis of hMR tran-
allowed the establishment of the relative abundance ofscripts was performed using skin biopsies of patients with
mMR transcripts among tissues that was subsequentlyhyperaldosteronism or hypoaldosteronism. The expres-
used as a basis to compare transgene expression drivension of exon 1b-containing transcripts was significantly
by each of the hMR promoters. We showed that colonreduced in sweat gland ducts of patients with Conn’s and
always contains the highest levels of mMR mRNA. TheLiddle’s syndromes, both characterized by an increased
receptor was also expressed at a relatively high level inrenal sodium reabsorption associated with extracellular
the lung, salivary glands, brain, and testis. The uterus,volume expansion and hypertension, resulting from in-
kidney, heart, skin, muscle, and spleen were also showncreased aldosterone production and from constitutive
to express substantial amounts of mMR.activation of the amiloride-sensitive epithelial sodium
The transgene messenger pattern of expression waschannel, respectively [39–41]. In contrast, hMR levels
then examined in various tissues of transgenic animalswere in the normal range in a subject affected by type
together with that of endogenous mMR by RNAse pro-I pseudohypoaldosteronism, a form of mineralocorticoid
tection assays. We first showed that the presence of TAgresistance associated with high circulating aldosterone
did not modify mMR expression. In the P1.TAg mice,levels [42]. Altogether, our results strongly suggested the
TAg and mMR were coexpressed in all tissues tested. Asexistence of novel tissue-specific hMR variants that we
expected, hibernomas and brown adipose tissue (BAT),are currently trying to identify and characterize. More-
which kept a normal histologic appearance in youngerover, we have demonstrated that the expression of exon
animals, expressed very high levels of TAg. The relative1a- and 1b-containing transcripts are regulated in a tis-
tissue-specific distribution of TAg in P1.TAg mice com-sue-specific manner, and that these splice variant levels
pared with that of mMR revealed some differences: theseem to be differentially affected by sodium overload
transgene messenger amount was low in colon but farrather than by plasma aldosterone concentrations. It
exceeded that of mMR in salivary glands and testis. Trans-might be particularly interesting to investigate whether
gene content was lower than that of mMR in kidney,modifications of intracellular osmolarity and/or sodium
but immunohistochemistry with an anti-TAg antibodycontent could influence hMR gene expression.
showed that cellular localization of TAg was similar to
renal expression of MR, with a nuclear labeling exclu-
TARGETED ONCOGENESIS AND TISSUE- sively observed over the distal parts of the nephron.
SPECIFIC USE OF P1 AND P2 PROMOTERS Thus, the P1 promoter seems to be transcriptionally ac-
To analyze P1 or P2 hMR alternative promoters func- tive in all MR-expressing tissues since P1-driven trans-
tions in vivo and to establish new cell lines derived from gene expression recapitulates that of the endogenous
receptor. In addition, our data strongly suggested thatMR-expressing tissues, we have generated transgenic
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P1 promoter could be used to drive expression of any involved in thermogenesis, is a specific marker of brown
transgene in the renal MR-sensitive cells. In contrast, fat. Unlike undifferentiated cells, after stimulation by
P2.TAg mice exhibited a rather low transgene expression isoproterenol or retinoic acid, fully differentiated T37i
in all organs with a variable localization among trans- cells expressed UCP1 mRNA. Both differentiated, un-
genic mice. No transgene was detected in colon and skin differentiated T37i, T34, and T37s cells expressed low
in any animal. Unlike line 54, line 45 animals expressed but detectable amounts of mMR mRNA, as assessed
TAg in kidney, whereas TAg was only found in the by RPA. Specific aldosterone-binding sites were also
salivary glands of founder 55. This could indicate a strong detected in the cytosolic fraction of undifferentiated
influence of the transgene integration site on the tissue- T37i, consistent with the presence of a functional mMR
specific expression driven by P2 promoter. Conversely, protein in these cells. mMR transcripts were also present
cerebral or facial tumors and hyperplastic thymus ex- in the BAT of wild-type mice and in P1.TAg mice hiber-
pressed high levels of TAg. It is worth noting that the nomas, indicating that brown adipocytes represent new
line 54 F2 generation animals, which did not develop aldosterone-target cells [43]. Furthermore, we have shown
PNET, did not express transgene in the brain [Le Menuet that aldosterone treatment of T37i cells induced adipo-
et al, J Biol Chem 2000 (in press)]. cyte differentiation with a dose-dependent and mineralo-
Our results demonstrated a distinct tissue-specific uti- corticoid-specific increase in triglyceride content. This
lization and strength of proximal and distal hMR pro- is in accordance with previous report on aldosterone-
moters. Indeed, P1 promoter drives a similar expression mediated differentiation of 3T3-L1 cells, a cellular model
pattern than endogenous mMR regulatory sequences, of white adipocytes [44]. This process was accompanied
most notably in the kidney. Furthermore, both in vitro by a stimulation of early adipogenic gene markers ex-
and in vivo studies showed that P1 activity is approxi- pression such as lipoprotein lipase, PPARg, and adipo-
mately 10 times stronger than that of P2. We could hy- cyte-specific fatty acid binding protein (aP2) (Penfornis,
pothesize that P1 might govern tissue specificity and the manuscript submitted for publication; abstract, Zennaro
level of MR expression, while P2 could be implicated et al, 80th Annual Meeting Endocrine Society, New Or-
in the fine-tuning regulation depending of physiological leans, 1998). Collectively, our results indicate that aldo-
states. sterone and MR participate in the very early induction
Another important aspect of our targeted oncogenesis of brown adipocyte differentiation program and provide
strategy was the development of different cell lines de- strong evidence that MR, besides its involvement in hy-
rived from neoplastic as well as normal tissues of P1 and droelectrolytic homeostasis, also plays a role in the regu-
P2.TAg transgenic mice. Indeed, we have successfully lation of energy balance. This is supported by prelimi-
established P1.TAg cell lines originating from hiberno-
nary results demonstrating that aldosterone actually
mas (T34, T37s, and T37i) [43], the whole brain (F6),
inhibited transcription and function of the mitochondrialhippocampus (BZ), lung (PP), salivary glands (SAL),
uncoupling protein 1 in brown adipocytes (abstract;glabrous skin of palms (PAL), and liver (LUCA) [Le
Lombe`s et al, 81st Annual Meeting Endocrine Society,Menuet et al, J Biol Chem 2000 (in press)]. Unfortu-
San Diego, 1999).nately, despite several attempts and appropriate trans-
Some other cellular models originating from variousgene expression, no cellular model was obtained from
nonneoplastic tissues of P1.TAg mice are currently underisolated cardiomyocytes or various tubular segments of
characterization, most of them expressing TAg mRNAthe distal nephron. In contrast, cellular models from
and protein as well as mMR messenger. Of particularP2.TAg mice could only be derived from leiomyosarco-
interest are the PP cells from mouse 44 lung and PALmas (JO, LIPT, and AXI). This could be related to the
cells from mouse 18 palmary skin. The MUC-1 tran-very low level of TAg expression in normal tissues of
scripts, a gene specifically expressed in glandular epithe-these animals. Incidentally, we failed to obtain cell lines
lial cells, for instance in bronchi [45, 46], were detectedfrom PNET.
by reverse transcription-polymerase chain reaction (RT-Among the cell lines derived from P1.TAg mice hiber-
PCR) in PP cells. We also demonstrated the presencenomas, one of them, the T37i cell line, was extensively
of involucrin mRNA in PAL cells by the same technique,characterized. Under normal culture conditions, T37i
this gene being a specific marker of granulous and spi-cells present a fibroblastic-like appearance. After con-
nous layer of the epidermis [47]. If a functional mMRfluence and treatment with insulin and triiodothyronine,
protein could be detected in these cell lines, they maywhich are known to induce adipocyte differentiation,
constitute useful cellular models to further examine min-cells became larger and numerous intracytoplasmic vacu-
eralocorticoid action in the lung and epidermis and tooles appeared, consisting of small lipid droplets, as shown
identify target genes, which are induced or repressed byby red oil staining. Most of the cells presented with
aldosterone at the transcriptional level. Other cell linesmultiple nuclei and achieved terminal adipocyte differ-
entiation. The uncoupling protein 1 (UCP1), which is derived from the central nervous system, the liver, or
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the smooth muscle tumor could also represent potential We are currently trying to analyze and correlate the
interesting systems for the same type of investigations. tissue-specific expression of the recombinant MR at both
In summary, we have demonstrated that MR expres- mRNA and protein level and the phenotype of the ani-
sion is broader than initially thought and involves com- mals. A precise evaluation of renal, cardiovascular, and
plex regulatory mechanisms. The two hMR promoters endocrine functions should allow definition of functional
clearly differ by their relative potency and their differen- consequences of targeted hMR overexpression. This will
tial tissue-specific utilization in vivo. Finally, establish- be performed in a center dedicated to investigations on
ment of novel mineralocorticoid-sensitive cell lines by small living animals (Centre d’Explorations Fonctionnel-
targeted oncogenesis should facilitate further studies on les Inte´gre´es), which should open shortly in Bichat Medi-
molecular mechanisms of aldosterone action. cal School (Paris, France). At the molecular level, an
extensive study on tissue-specific gene expression using
a mouse cDNA array technique will be performed onTARGETED OVEREXPRESSION OF
normal and transgenic mice. This should provide newHUMAN MINERALOCORTICOID
information on modulation of MR-sensitive target genes,
One approach to gain new insights into MR function most notably those induced or repressed by aldosterone
is the generation of knockout mice. Animals with null at the transcriptional level. Identification and character-
mutation in the MR gene die 10 days after birth [48, 49], ization of such specific genes will provide a basis for
with symptoms resembling to pseudohypoaldosteronism candidate genes involved in renal and cardiac pathophys-
type I in which mutations in hMR gene have been docu- iologies.
mented [50]. We decided to use an alternative genetic
approach to elucidate the physiological functions played
CONCLUSIONby MR in different tissues. Transgenic mouse models
are currently being developed. We used the P1 or P2 Our transgenic mouse models have provided impor-
promoter to drive expression of recombinant hMR in a tant information on the molecular basis of hMR expres-
tissue-specific manner in order to create potential phys- sion in vivo. We have shown that the regulation of its
iopathologic models. Five independent transgenic lines tissue-specific expression is controlled by a complex sys-
were generated with P1.hMR construct and three with tem that involves the use of two alternative promoters
P2.hMR construct. Phenotypic characterization of these and the generation of at least two variant messengers
transgenic animals is currently ongoing. Preliminary ob- and probably some other hMR isoforms that render the
servations reveal the existence of major renal abnormali- mineralocorticoid signaling system even more complex.
ties in P1-hMR line 42 animals. Transgenic mice (approx- The aldosterone-activated MR was originally described
imately 25%) presented renal kystic formations, often as a major regulator of sodium reabsorption in tight epi-
associated with renal atrophy and hypertrophy of the thelia, we proposed that MR also plays an important role
opposite kidney. Some of them exhibited biological stig- on other nonepithelial target cells. The physiopathological
mas of renal failure. In addition, systematic histologic effects of aldosterone and mineralocorticoid selectivity-
examination identified nephropathies with dilation of conferring mechanisms remain to be fully elucidated.
Bowman’s spaces, tubular lumen, and interstitium to- Experimental MR-overexpressing animals represent suit-
gether with vacuolization of some tubular cells. Whether able systems to explore the widespread and pleiotropic
these major histologic alterations observed in most P1- functions of MR in vivo. Other transgenic mouse models
hMR animals are due to a direct or indirect effect of using both tissue-specific promoters, including appro-
renal hMR overexpression remains to be established. priate fragments of hMR promoters and MR variants,
Moreover, echocardiographic assessment of ventricle should certainly be helpful to further examine mineralo-
functions in 12-week-old P1-hMR mice disclosed a sig- corticoid signaling pathways.
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